Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

The goal of this clinical trial is to evaluate the efficacy and safety of cadonilimab in combination with paclitaxel, cisplatin, and radiation therapy for the treatment of locally recurrent and oligometastatic endometrial carcinoma. The main questions it aims to answer are: 1. Does the combination therapy improve the overall response rate (ORR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and safety in participants? 2. What are the predictive biomarkers of treatment efficacy, and how can this information better guide the use of immune-oncology drugs in

Trial Details

NCT ID
NCT06532539
Phase
PHASE2
Sponsor
Shandong Cancer Hospital and Institute
Status
RECRUITING
Cancer Type
Endometrial Cancer Uterine Cancer
Interventions
  • Paclitaxel and Cisplatin
  • Cadonilimab
  • Radiotherapy
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • A written informed consent form must be signed before the implementation of any trial-related procedures.
  • Female, aged 18 years or older and 80 years or younger.
  • ECOG PS 0-1.
  • Newly diagnosed with histologically or cytologically confirmed primary endometrioid adenocarcinoma, serous carcinoma, clear cell adenocarcinoma, un…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Endometrial Cancer Uterine Cancer Trials on Trialify →